Get the Stockscreener App
3.40
3.82%
0.13
Affimed N V stock is traded at $3.40, with a volume of 62,689.
It is up +3.82% in the last 24 hours and up +5.76% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$3.27
Open:
$3.24
24h Volume:
62,689
Relative Volume:
0.81
Market Cap:
$51.28M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-4.3623
EPS:
-0.7794
Net Cash Flow:
$-132.44M
1W Performance:
+1.34%
1M Performance:
+5.76%
6M Performance:
-37.36%
1Y Performance:
-6.94%
1-Day Range:
$3.24
$3.40
1-Week Range:
$3.159
$3.395
52-Week Range:
$2.9178
$8.95
Affimed N V Stock (AFMD) Company Profile
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
Affimed Announces Acceptance of Three Abstracts at the 2024 - GlobeNewswire
Affimed N.V. Announces Acceptance of Three Abstracts At the 2024 Ash Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma - Marketscreener.com
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Affimed (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - MarketBeat
683 Capital Management, LLC Expands Stake in Affimed NV - Yahoo Finance
Affimed Appoints New Director Amid Strategic Moves - TipRanks
Affimed N : Annual General Meeting Results Form 6 K - Marketscreener.com
Affimed N : Presentation - Marketscreener.com
Analysts Set Affimed (NASDAQ:AFMD) Target Price at $20.00 - MarketBeat
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Affimed appoints Shawn Leland as chief executive officer - MSN
Affimed (NASDAQ:AFMD) Sees Significant Decrease in Short Interest - MarketBeat
AFMDAffimed N.V. Latest Stock News & Market Updates - StockTitan
Affimed N.V. Announces Upcoming EGM - TipRanks
Affimed to Present at the Cantor Global Healthcare Conference 2024 - GlobeNewswire
Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Affimed (NASDAQ:AFMD) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Affimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Affimed (NASDAQ:AFMD) - MarketBeat
Earnings call: Affimed reports promising clinical results and stable finances By Investing.com - Investing.com Australia
Earnings call: Affimed reports promising clinical results and stable finances - Investing.com
Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: F - GuruFocus.com
Affimed N.V.: Q2 Earnings Snapshot - New Haven Register
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - Yahoo Finance UK
Stifel holds Affimed at $5 target with new CEO at helm By Investing.com - Investing.com Canada
Stifel holds Affimed at $5 target with new CEO at helm - Investing.com
Affimed Appoints Shawn M. Leland as Chief Executive Officer - Yahoo Finance UK
Affimed Reports Second Quarter 2024 Financial Results & Business Update - Yahoo Finance UK
Affimed NV reports results for the quarter ended in June 30Earnings Summary - xm.com
Affimed reports Q2 EPS (EUR1.01) vs. (EUR1.97) last year - TipRanks
Affimed N.V. Faces Substantial Mid-Year Losses - TipRanks
Affimed N.V.: Q2 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts - Seeking Alpha
Affimed NV (AFMD) Q2 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Affimed names Shawn Leland as new CEO By Investing.com - Investing.com Canada
Affimed appoints Shawn Leland as Chief Executive Officer - TipRanks
Affimed Appoints New CEO to Bolster Growth - TipRanks
Affimed names Shawn Leland as new CEO - Investing.com
Affimed (AFMD) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024 - GlobeNewswire
Affimed (NASDAQ:AFMD) Stock Price Crosses Below 200 Day Moving Average of $5.35 - Defense World
Affimed (NASDAQ:AFMD) Stock Crosses Below 200 Day Moving Average of $5.35 - MarketBeat
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):